Lord Abbett & CO. LLC Buys 13,687 Shares of Becton, Dickinson and Company (NYSE:BDX)

Lord Abbett & CO. LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 8.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 180,948 shares of the medical instruments supplier’s stock after acquiring an additional 13,687 shares during the period. Lord Abbett & CO. LLC owned about 0.06% of Becton, Dickinson and Company worth $41,448,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company in the first quarter worth approximately $27,000. REAP Financial Group LLC raised its stake in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 55 shares in the last quarter. Alpine Bank Wealth Management bought a new position in Becton, Dickinson and Company in the first quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its stake in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares in the last quarter. Finally, Nexus Investment Management ULC bought a new position in Becton, Dickinson and Company in the first quarter worth approximately $34,000. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Barclays reduced their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. William Blair downgraded Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Raymond James Financial lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Friday, May 2nd. Finally, Bank of America cut Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target for the company. in a report on Thursday, May 1st. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $211.44.

Read Our Latest Research Report on BDX

Becton, Dickinson and Company Stock Down 0.4%

Shares of NYSE BDX opened at $195.25 on Friday. The company has a 50 day simple moving average of $177.75 and a 200-day simple moving average of $197.66. The company has a market capitalization of $55.97 billion, a P/E ratio of 35.12, a P/E/G ratio of 1.47 and a beta of 0.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter last year, the firm earned $3.50 EPS. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 863 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the sale, the director owned 23,143 shares in the company, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,214 shares of company stock worth $579,206. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.